Legend Biotech (LEGN) has released an update.
Legend Biotech has announced promising results from their Phase 2 and Phase 3 studies of CARVYKTI® in treating multiple myeloma, showing significant improvements in patient outcomes, including deep and durable responses and improved progression-free survival compared to standard therapies. The data, which were presented at key medical conferences, underpin the FDA’s recent approval of CARVYKTI® for use after just one prior line of therapy. Despite strong efficacy, the treatment has also shown a consistent safety profile, with serious adverse events such as cytokine release syndrome and neurologic toxicities.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
